Status:
COMPLETED
Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study will assess safety and efficacy of AEB071 combined with everolimus in a CNI-free (calcineurin inhibitor) regimen in renal transplant recipients.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patient has been maintained on study drug for 12 months in the core study
- Exclusion criteria:
- Not applicable
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT00820911
Start Date
September 1 2008
End Date
July 1 2012
Last Update
February 24 2017
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
San Martín, Buenos Aires, Argentina, C1107BEA
2
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina, X5022CPU
3
Novartis Investigative Site
Camperdown, New South Wales, Australia, 2050
4
Novartis Investigative Site
Woodville, South Australia, Australia, 5011